

YEAR-END REPORT
MAY 2022 – APRIL 2023
INTEGRUM AB (PUBL)



Integrum

CONTINUING TO BUILD THE COMPANY

FOURTH QUARTER 2022/23 (FEBRUARY – APRIL)

- Net sales amounted to SEK 18.1 (18.3) million, which is a decrease of 1.1% compared with the corresponding period last year.
- Operating profit amounted to SEK -7.2 (-0.5) million.
- Profit/loss after tax amounted to SEK 6.4 (3.3) million, which resulted in earnings per share of SEK 0.35 (0.18).
- Cash flow from operating activities before changes in working capital amounted to SEK -6.4 (-0.0) million. Liquid assets as of 30 April 2023 amounted to SEK 41.9 (75.3) million.
- Currency fluctuations continue to affect the company operating profit, although to a lesser degree than earlier in the year. During the quarter the operating result was negatively affected with -420 KSEK from currency effect on intragroup Accounts receivables (AR).
- The end of Q4 saw an improved cash flow reinforcing the management position that the business has the liquid assets needed for further growth.

Significant events in the quarter

- The company is continuing to expand and develop the organisation. During the period, the company welcomed four new employees: three at Integrum AB and one at Integrum Inc.
- Work on the transition to certification according to MDR continued, albeit at a lower intensity and with reduced expenses, as the certification was granted in the period. During the quarter, costs of SEK 1.4 million were capitalized as intangible assets. The costs refer to external costs as well as time spent internally.
- Shirley Ryan AbilityLab received a USD 1.5 million grant from the US Department of Defense. The grant will finance a clinical trial to examine the benefits of Integrum's e-OPRA™ Implant System compared to a traditional socket prosthesis system.

1 MAY 2022 – 30 APRIL 2023 (12 MONTHS)

- Net sales amounted to SEK 74.3 (55.7) million, an increase of 33.3% compared with the corresponding period in the previous year.
- Operating profit amounted to SEK -19.7 (1.0) million.
- Profit after tax amounted to SEK -3.7 (21.3) million, which resulted in earnings per share of SEK -0.2 (1.19).
- Cash flow for the period from operating activities before changes in working capital amounted to SEK -26.2 (2.5) million.

Significant events in the year

- The board appointed Rickard Brånemark as the company's new CEO. In connection with this, Rickard Brånemark resigned as Chair of the Board, and Bengt Sjöholm was appointed Chair of the Board.
- During the period Integrum received the MDR certificate for its OPRA™ Implant System.
- United States Patent and Trademark Office approved patent for the OPRA™ Implant System. The system is now patent protected until 2044 in the US.
- The company received ISO 13485 certification during the year. This is a part of the investments done in the MDR project. It is now verified that Integrum's QMS system is appropriate and meet regulatory medical device requirements.

GROUP KEY RATIOS

	February – April		May – April	
	2022/23	2021/22	2022/23	2021/22
Net sales, SEK thousand	18,131	18,323	74,272	55,724
Net sales growth (%)	-1.1	47.4	33.3	29.3
Operating profit/loss, SEK thousand	-7,171	-468	-19,704	1,039
Profit/loss after financial items, SEK thousand	-7,681	-317	-21,523	1,185
Balance sheet total, SEK thousand	164,976	180,371	164,976	180,371
Equity/assets ratio, %	86.9	88.5	86.9	88.5
Number of employees at end of period	33	29	33	29
Equity per share, SEK	7.8	9.0	7.8	9.0
Share price closing date, SEK	26.15	42	26.15	42
Market value on balance sheet date, SEK million	463.0	747.7	463.0	747.7

For definitions, see page 16.

CEO's statement

Continuing to build the company. Integrum's revenues amounted to SEK 18.1 million during the fourth quarter (February-April), similar to Q4 last year and Q3 this year. We are confident that the growth decline is temporary, and the building blocks we are putting in place will deliver continued long-term growth. These building blocks include, regulatory approvals, a strengthened IP portfolio, key recruitments, awareness campaigns, and research grants. Over the year, we have continued to see strong growth in our sales of 33 %, and we remain committed to building a global orthopaedic company.

Awareness campaigns drive future growth

During recent months we have invested in raising awareness about our implant systems in social media campaigns in the U.S., on platforms like Instagram, Facebook, and LinkedIn. The goal is to build awareness amongst prospective patient groups – like veterans, trauma, and bone cancer patients – and educate them about our superior alternative to sockets. Also, we have turned to professionals to build awareness amongst orthopaedic surgeons, trauma surgeons, rehabilitation specialists, and prosthetists about Integrum and OPRA™ Implant System. The campaigns have already been shown to significantly increase the number of followers on social media and generate an increased reach measured in impressions and engagement. From now on, we plan to maintain a strong social presence on both patient and professional channels, and the increased interest is expected to generate a growing patient pipeline. We have over 50 hospitals using our implants, and we can now focus on increasing the number of patients treated at these hospitals.

MDR certificate facilitates future scale-up in Europe

We finally received the EU Medical Device Regulation (MDR) certificate for our OPRA™ Implant System in the beginning of March. The certification reflects that our product and Quality Management System meet all the requirements of the new EU regulations for medical devices. It also shows that we are at the forefront in terms of quality assurance and regulatory affairs and gives us an edge over competitors in the osseointegration area. The certificate also marks the end of an intense, resource- and

cash-demanding process, and we can now fully focus on our scale-up in Europe.

e-OPRA attracts prestigious research grants

In March, Shirley Ryan AbilityLab – a top-ranked physical medicine and rehabilitation hospital based in Chicago – received a USD 1.5 million grant from the US Department of Defense. The grant will finance a clinical trial to examine the benefits of Integrum's e-OPRA™ Implant System compared to a traditional socket prosthesis system in above knee amputees

Strengthening our board with strategic know-how

In May, the board announced the appointment of Scott Flora as an adjunct board member. Scott Flora has vast experience from strategic and leadership roles in the healthcare sector and a great understanding of how the orthopaedic industry works, especially in the U.S. He has previously contributed to Integrum's business development in the role of Strategic Advisor, and we are now very excited that he has chosen to expand his commitment to the company. We have strengthened the management team with a Chief Operating Officer, a new Head of QARA, and a new Supply Chain Manager, and we have recently moved to a new office at the GoCo House. We are well prepared for the continued expansion of our business.

Summarizing the quarter, we are further strengthening our business in several areas. Key recruitments, a strong IP and regulatory platform, the MDR certification give us a great opportunity to scale up our business in Europe, the awareness campaigns in the US will drive continued growth, not only in the US but over time also in Europe and our own investment in R&D will, together with grants, support the further development of our next-generation implant system e-OPRA™. I am convinced we remain on track to become a global leader in our field.

Mölnådal, 8 June 2023

Rickard Brånemark
Chief Executive Officer

Fourth quarter 2022/23 (February – April)

Net sales

Net sales for the fourth quarter of the year amounted to SEK 18.1 (18.3) million, a decrease of -1.0% compared with the same period in the previous year. For revenue per market, see note 4 on page 16.

In the quarter, the US market accounted for 78% (79%) of net sales. During the quarter a top ranked hospital received a USD 1.5 million grant from the US Department of Defense grant to finance a clinical trial to examine the benefits of Integrum's OPRA™ Implant System compared to a traditional socket prosthesis system in three individuals with lower-limb amputations.

In markets outside the US, most sales continue to come from Sweden, Germany and Australia, as well as the new centre in Norway. During the quarter Integrum received an EU Medical Device Regulation (MDR) certificate for the OPRA™ Implant System. With this, the company is provided continued freedom of operation to commercialize its products within the EU. Also, in the period the company received a patent approval in Australia describing components and design features of the OPRA™ Implant System. The patent period extends until 2037 and will further strengthen the company's position in the Australian market.

Costs and profit/loss

The cost of goods sold amounted to SEK -3,424 thousand, corresponding to a gross margin of 81% (83%). The gross margin is affected by the distribution between the OPRA™ Implant System and the Axor™ safety coupling. The gross margin is also charged by the variable compensation that the company's contracted sellers receive, primarily in the US, in connection with product sales.

Other external costs during the quarter amounted to SEK -9,898 (-10,969) thousand. Sales and marketing costs during the period amounted to SEK -5,067 (-5,193) thousand, corresponding to 51% (47%) of other external costs.

Employee benefit expenses during the period amounted to SEK -11,057 (-8,162) thousand. During the period, employee benefit expenses of SEK 0 (1,078) thousand were capitalized for work related to the ongoing MDR certification. The increase between periods is due to new recruitment.

The company is in an expansion phase but estimates that the increase in employee benefit expenses will not continue in the next quarter.

The net currency effects had a negative impact of SEK -420 thousand on the quarter's operating profit, attributable among other things to the translation of the receivables from the subsidiary company Integrum Inc. at the rate on the balance sheet date. The positive currency effect is recognised as other operating income, which during the quarter amounted to SEK 720 thousand. Negative currency effects are recognised as other operating expenses and amounted to SEK -1,122 thousand during the quarter.

During the quarter, SEK 1,403 (12,623) thousand was capitalized as intangible assets. The costs refer to other external costs as well as time spent internally. The expenses refer to expenditure for activities related to the ongoing transition from certification according to MDD (the former European Medical Device Directive) to the more comprehensive MDR (Medical Device Regulation). The company estimates that expenses related to this work will decrease substantially in scale in the coming quarters.

Total depreciation/amortization amounted to SEK 502 (320) thousand during the quarter. Depreciation/amortization attributable to the application of IFRS 16 amounted to SEK 414 (174) thousand. The remaining amount relates to depreciation of patents granted.

Cash flow

During the period February – April 2022/23 cash flow from operating activities before changes in working capital amounted to SEK -5,728 thousand as compared with SEK 3 thousand for the corresponding period in 2021/22.

Cash flow from changes in working capital amounted to SEK 3,781 (-5,501) thousand. Inventories and accounts receivable decreased on the asset side, and the company's operating liabilities increased during the quarter.

Cash flow from investing activities amounted to SEK -1,732 (-12,739) thousand. The costs refer to other external costs as well as time spent internally in relation to the MDR certification.

Cash flow from financing activities amounted to SEK -42 (-289) thousand.

Period 2022/23 (1 May 2022 – 30 April 2023)

Net sales

Net sales for the full year amounted to SEK 74.3 (55.7) million, an increase of 33.3% compared with the previous year. For revenue per market, see note 4 on page 16.

In the period, the US market accounted for 78.7% (77.3%) of net sales.

Costs and profit/loss

The cost of goods sold amounted to SEK -16.703 thousand, corresponding to a gross margin of 77.5% (79%).

Other external costs during the period amounted to SEK -45,334 (-29,580) thousand. Sales and marketing costs during the period amounted to SEK -21,651 (-11,863) thousand, corresponding to 48% (40%) of other external costs. The increase between the periods can be attributed among other things to increased marketing activities, primarily in the US, as well as participation in trade fairs in both the US and Germany during the period.

Employee benefit expenses during the period amounted to SEK -39,641 (-25,825) thousand. During the period, employee benefit expenses of SEK 3,273 (2,431) thousand were capitalized for work related to the ongoing MDR certification. The increase between the periods is due to new recruitment. The company is in an expansion phase and estimates that employee benefit expenses may increase in the coming quarters.

Unrealised currency effects had a positive impact of SEK 5,584 thousand on the period's operating profit/loss, attributable among other things to the translation of the receivable from the subsidiary company Integrum Inc. at the rate on the balance sheet date.

A positive currency effect is recognised as other operating income, which during the period amounted to SEK 20,970 thousand. Negative currency effects are reported as other operating expenses and during the period amounted to SEK -15,386 thousand.

During the period, a total of SEK 11,074 (29,461) thousand was capitalized as intangible assets. The expenses refer to expenditure related to the ongoing transition from certification in accordance with MDD to MDR. Total depreciation/amortization amounted to SEK 1,115 (1,264) thousand in the period, of which SEK 175 (117) thousand derives from depreciation of expenditure for regulatory approval in the US.

Depreciation/amortization attributable to the application of IFRS 16 amounted to SEK 414 (697) thousand. The remaining part relates to depreciation of patents granted.

Cash flow

During the period May – April 2022/23, cash flow from operating activities before changes in working capital amounted to SEK -26,202 thousand compared with SEK 2,449 thousand for the corresponding period in 2021.

Cash flow from changes in working capital amounted to SEK 744 (-22,842) thousand. Inventories have increased and accounts receivables have decreased on the asset side. On the liability side, accounts payable have decreased.

Cash flow from investing activities amounted to SEK -11,402 (-29,268) thousand. The costs refer to other external costs as well as time spent internally in relation to the ongoing MDR certification and the approved FDA PMA application.

Cash flow from financing activities during the period amounted to SEK 3,436 (117,322) thousand. Last year a rights issue was carried out. The exercise of warrants refers to incentive programs for the company's employees and board.

Financial position

As of 30 April 2023 the group's liquid assets amounted to SEK 41.9 million, with equity of SEK 143.3 million and the equity/assets ratio being 86.9%. As at 30 April 2022 the group's liquid assets amounted to SEK 75.3 million, with equity of SEK 159.7 million and the equity/assets ratio being 88.5%. Equity per share amounted to SEK 7.8 (9.0) as at 30 April 2023.

Parent company

In the period the parent company Integrum AB moved to new office spaces. The relocation took place in April 2023. The new office space is located at GoCo Health Innovation City located in Gothenburg.

Future prospects

We have continued to work on our focus areas such as creating awareness. One such activity is to host OPRA™ Insight Forums in the US. These events are a good way for potential patients to meet surgeons, company representatives and amputees who have already made the decision and completed the treatment.

In all ongoing discussions with payers, health economic evidence is key. We are therefore continuously working on collecting data to compile convincing evidence for the economic benefits of using OPRA™ Implant System. In November, one such analysis was presented at the American Congress of Rehabilitation Medicine (ACRM) meeting. The research concluded that the OPRA™ Implant System is a cost effective solution for above knee amputees.

Markets outside the US, especially Germany, are continuing to develop with new hospitals showing interest and starting up the treatment. Main portion of sales is coming from centers in Sweden, Norway, Germany, Benelux and Australia. The recovery after the pandemic has been faster in the US, but we are now starting to see that it is picking up outside the US too. However, full recovery lies still in the future.

We are continuing the expansion of our business in the US, which is key to our long-term growth. In parallel, investments are being made through partners in key markets within the EMEA, where we see opportunities, especially in the German market.

Work is continuing to create the conditions for a global, scalable business and a high-performing sustainable organisation, and thereby to ensure the successful commercialisation of our entire product portfolio.

The cash position, which on 30 April amounted to SEK 41,9 million together with 21,2 MSEK in secure accounts receivables, provides a solid basis for further broadening and strengthening the competence in the organisation and continued market investments for long-term strong growth.

Other information

Personnel and organisation

At the end of the period, the number of employees amounted to 33 (29), of which 14 (14) are women and 19 (15) men. Of these, 24 (22) were people employed in Sweden and 9 (7) in the US. In addition, the company is retaining external consultants as needed for individual projects. The cost of consultants is recognised as other external costs.

Related party transactions

During the period, companies related to Chair of the Board Rickard Brånemark invoiced the company SEK 598 thousand for clinical expertise work during the period. The cost has been recognised in other operating expenses.

No other transactions that significantly affected the company's profit/loss or financial position were performed with related parties during the quarter or period.

Significant risks and uncertainties

Integrum strives to continually identify, evaluate and manage risks in different systems and processes. Risk analyses are performed continually in connection with normal operations and major activities.

This report has not been reviewed by the company's auditors.

Financial statements

Interim reports and other financial reports are available at www.integrum.se

Upcoming reports

- The annual report for the 2022/23 financial year will be published in week 35 of 2023
- The interim report for the first quarter 2023/24 will be published on 31 August 2023
- The interim report for the second quarter 2023/24 will be published on 4 December 2023
- The interim report for the third quarter 2023/24 will be published on 29 February 2024
- The year-end report for the 2023/2024 financial year will be published on 30 May 2024

The most significant strategic and operational risks that affect the company's business and industry are described on page 5 of the company's annual report for the 2021/2022 financial year. The main risks and uncertainties include market risks, seasonal risks, currency risks, permits and certifications, product quality, dependence on suppliers and liquidity risks. The reported risks as described in the annual report are deemed to be essentially unchanged.

Events after the balance sheet date

After the end of the period, the board appointed Scott Flora as an adjunct board member.

There are no other significant events to report after the end of the period.

Assurance

The board of directors and the CEO declare that the year-end report gives a full and fair view of the operations, position and performance of the parent company and group and describes the significant risks and uncertainty factors faced by the parent company and the companies included in the group.

Mölnadal, 8 June 2023

Rickard Brånemark
Chief Executive Officer
and Board Member

Bengt Sjöholm
Chair of the Board

Artur Aira
Board Member

Andrew Christensen
Board Member

Patric Lindgren
Board Member

Karin Johansson Wingstrand
Board Member

Cecilia Wikström
Board Member

Trading venue and Certified Adviser

Since 15 May 2017 Integrum's share has been listed on Nasdaq First North Growth Market.

The company's Certified Adviser is Erik Penser Bank
Tel. no.: +46 (0) 8-463 83 00

E-mail: certifiedadviser@penser.se

Please refer any questions to

Rickard Brånemark, CEO
Tel. no.: +46 (0) 708-46 10 61
rickard.branemark@integrum.se

Jörgen Svanström, CFO
Tel. no.: +46 (0) 707 34 96 60
jorgen.svanstrom@integrum.se

CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME

Amounts in SEK thousand	Note	February – April		May – April	
		2022/2023	2021/2022	2022/2023	2021/2022
Net sales	4	18,131	18,323	74,272	55,724
Work performed by company for own use and capitalized		-	1,078	3,273	2,431
Other operating income	5	702	5,666	20,970	18,527
Total		18,833	25,066	98,515	76,682
Raw materials and consumables		-3,424	-3,162	-16,703	-11,597
Other external costs	7	-9,898	-10,969	-45,334	-29,580
Employee benefit expenses		-11,057	-8,612	-39,641	-25,825
Depreciation and impairment of intangible assets		-502	-320	-1,155	-1,264
Other operating expenses	6	-1,122	-2,450	-15,386	-7,377
Total expenses		-26,004	-25,514	-118,219	-75,643
Operating profit		-7,171	-468	-19,704	1,039
Financial income		-384	151	-328	308
Financial expenses		-126	-	-1,491	-163
Net financial items		-510	151	-1,819	146
Profit after financial items		-7,681	-317	-21,523	1,185
Profit/loss before tax		-7,681	-317	-21,523	1,185
Income tax	11	14,070	3,590	17,802	20,088
Profit/loss for the period		6,389	3,272	-3,722	21,272
Other comprehensive income:					
<i>Items that may be reclassified for the net profit/loss for the period</i>					
Exchange rate differences when translating foreign operations		-9,643	-1,675	-16,602	-4,331
Other comprehensive income for the period		-9,643	-1,675	-16,602	-4,331
Total comprehensive income for the period		-4,741	1,598	-21,811	16,941

The profit/loss and comprehensive income for the period are wholly attributable to parent company shareholders.

Earnings per share, calculated on the profit/loss for the period attributable to parent company shareholders:

Amounts in SEK	Note	February – April		May – April	
		2022/2023	2021/2022	2022/2023	2021/2022
Earnings per share before dilution	8	0.35	0.18	-0.2	1.19
Earnings per share after dilution	8	0.35	0.18	-0.2	1.17

STATEMENT ON CONSOLIDATED FINANCIAL POSITION

Amounts in SEK thousand	Note	30/04/2023	30/04/2022
ASSETS			
Non-current assets			
Intangible assets			
Capitalized expenditure for development work and similar work		42,031	30,973
Concessions, patents, licences, trademarks and similar rights		13	389
Total intangible assets		42,043	31,363
Tangible assets			
Machines, equipment and furniture		329	-
Total tangible assets		329	
Right of use		7,832	349
Deferred tax assets	11	27,208	21,903
Total non-current assets		77,412	53,614
Current assets			
Inventories			
Finished goods and goods for resale		21,081	20,119
Total inventories		21,081	20,119
Current receivables			
Accounts receivable		21,205	24,106
Tax assets		609	414
Other receivables		261	-
Prepaid expenses and accrued income		2,486	6,799
Liquid assets		41,921	75,319
Total current receivables		66,482	106,638
Total current assets		87,563	126,757
TOTAL ASSETS		164,976	180,371

STATEMENT ON CONSOLIDATED FINANCIAL POSITION cont.

Amounts in SEK thousand	Note	30/04/2023	30/04/2023
EQUITY			
Share capital		1,275	1,275
Other contributed capital		209,867	205,921
Reserves		-19,328	-2,726
Profit/loss brought forward, including profit/loss for the period		-48,477	-44,755
Total equity attributable to parent company shareholders		143,338	159,715
LIABILITIES			
Long-term liabilities			
Other liabilities to credit institutions		-	-
Lease liabilities		6,424	-434
Total non-current liabilities		6,424	-434
Current liabilities			
Liabilities to credit institutions		-	232
Advance payments from customers		-	-
Accounts payable		6,514	10,800
Lease liabilities		1,491	711
Other current liabilities		1,589	1,163
Accrued expenses and deferred income		5,621	8,183
Total current liabilities		15,215	21,089
TOTAL EQUITY AND LIABILITIES		164,976	180,371

STATEMENT OF CHANGES IN CONSOLIDATED EQUITY

Amounts in SEK thousand	Note	Share capital	Other contributed capital	Reserves	Profit/loss brought forward (including profit/loss for the period)	Total equity
Opening balance on 1 May 2020		1,057	87,318	-827	-63,854	23,694
Profit/loss for the period					-2,149	-2,149
Other comprehensive income for the period				2,431		2,431
Total comprehensive income		0	0	2,406	-2,149	283
Transactions with shareholders						
New share issue		52	-52			0
Options			302			302
Total transactions with shareholders		52	250			302
Closing balance on 30 April 2021		1,109	87,568	1,605	-66,028	24,254
Opening balance on 1 May 2021		1,109	87,568	1,605	-66,028	24,254
Profit/loss for the period					21,272	23,703
Other comprehensive income for the period				-4,331		-4,331
Total comprehensive income		0	0	-4,331	21,272	16,941
Transactions with shareholders						
New share issue		166	117,092			117,258
Options			1,261			1,261
Total transactions with shareholders		166	118,353	0	0	118,519
Closing balance on 30 April 2022		1,275	205,921	-2,725	-44,755	159,715
Opening balance on 1 May 2022		1,275	205,921	-2,726	-44,755	159,715
Profit/loss for the period					-3,722	-3,722
Other comprehensive income for the period				-16,602		-16,602
Total comprehensive income		0	0	-16,602	-3,722	-21,811
Transactions with shareholders						
New share issue			3,110			3,110
Options			836			836
Total transactions with shareholders		0	3,946	0	0	3,946
Closing balance on 30 April 2023		1,275	209,867	-19,328	-48,477	143,338

CONSOLIDATED STATEMENT OF CASH FLOW IN SUMMARY

Amounts in SEK thousand	Note	February – April		May – April	
		2022/2023	2021/2022	2022/2023	2021/2022
Operating activities					
Profit/loss before financial items		-7,171	-468	-19,704	1,039
Interest received		-384	151	-328	308
Interest paid		-126	-	-1,491	-163
Adjustments for items not included in cash flow etc.		1,261	320	-4,678	1,264
Cash flow from operating activities before change in working capital		-6,419	3	-26,202	2,449
Cash flow from changes in working capital					
Changes in inventories		742	-4,887	-636	-10,905
Changes in operating receivables		1,577	-7,736	7,149	-17,991
Changes in operating liabilities		1,461	7,122	-5,770	6,054
Cash flow from operating activities		3,781	-5,501	744	-22,842
Investing activities					
Purchase of intangible assets		-1,731	-12,739	-11,402	-29,268
Cash flow from investing activities		-1,731	-12,739	-11,402	-29,268
Financing activities					
New share issue		-	-	3,110	117,092
Options		-	-	836	1,261
Leases		-	-226	-277	-777
Repayment of debt		-42	-63	-232	-254
Cash flow from financing activities		-42	-289	3,436	117,322
Cash flow for the period		-4,412	-18,526	-33,424	67,661
Liquid assets at the start of the period		46,332	93,846	75,344	7,658
Liquid assets at end of period		41,920	75,319	41,920	75,319

PARENT COMPANY INCOME STATEMENT IN SUMMARY

Amounts in SEK thousand	Note	February – April		May – April	
		2022/2023	2021/2022	2022/2023	2021/2022
Net sales	7	7,220	15,511	38,212	55,748
Work performed by company for own use and capitalized		-	1,078	3,273	2,431
Other operating income		133	5,675	18,299	18,532
Total		7,353	22,264	59,784	76,711
Raw materials and consumables		-708	-10,400	-5,968	-16,317
Other external costs	7	-5,003	-6,386	-25,843	-20,120
Employee benefit expenses		-6,693	-4,630	-23,114	-17,954
Depreciation of intangible assets		-89	-112	-393	-534
Other operating expenses		-17,523	-2,580	-29,823	-7,488
Total operating expenses		-30,015	-24,109	-85,141	-62,412
Operating profit		-22,663	-1,845	-25,357	14,298
Profit from financial items					
Interest income and similar income statement items		-384	131	-333	308
Interest expenses and similar income statement items		-3	-18	-1,370	-183
Total profit/loss from financial items		-387	114	-1,702	126
Profit after financial items		-23,050	-1,732	-27,060	14,424
Appropriations		24,380	340	24,380	340
Tax on profit for the period	11	-376	1,999	-1,202	6,341
Profit/loss for the period		954	608	-3,882	21,106

In the parent company there are no items that are recognised as other comprehensive income, which is why the comprehensive income for the period corresponds to the profit/loss for the period.

PARENT COMPANY BALANCE SHEET IN SUMMARY

Amounts in SEK thousand	Note	30/04/2023	30/04/2022
ASSETS			
Non-current assets			
Capitalized expenditure for development work		42,031	30,973
Concessions, patents, licences, trademarks and similar rights		13	389
Total intangible assets		42,043	31,363
Machines, equipment and furniture		328	-
Total tangible assets		328	-
Financial assets			
Participations in group companies		590	517
Deferred tax assets	11	5,598	8,056
Total financial assets		6,188	8,573
Total non-current assets		48,559	39,935
Current assets			
Inventories			
Finished goods and goods for resale		9,625	6,070
Total inventories		9,625	6,070
Current receivables			
Accounts receivable		282	3,108
Receivables from group companies		133,151	84,123
Tax assets		498	239
Other receivables		261	-
Prepaid expenses and accrued income		1,828	4,523
Total current receivables		136,020	91,994
Cash and bank balances		25,994	72,292
Total current assets		171,639	170,280
TOTAL ASSETS		220,198	210,216

PARENT COMPANY BALANCE SHEET IN SUMMARY cont.

Amounts in SEK thousand	Note	30/04/2023	30/04/2022
EQUITY AND LIABILITIES			
EQUITY			
Restricted equity			
Share capital		1,275	1,275
Statutory reserve		5	5
Total restricted equity		1,280	1,280
Non-restricted equity			
Share premium reserve		212,391	204,684
Profit or loss from previous period		-16,474	-33,243
Profit/loss for the period		-3,882	21,106
Total non-restricted equity		192,035	192,547
TOTAL EQUITY		193,316	193,827
LIABILITIES			
Long-term liabilities			
Other liabilities to credit institutions		-	-
Total non-current liabilities		-	-
Current liabilities			
Liabilities to credit institutions		-	232
Advance payments from customers		-	-
Accounts payable		4,742	9,606
Other current liabilities		1,589	1,163
Accrued expenses and deferred income		20,551	5,384
Total current liabilities		26,883	16,389
TOTAL LIABILITIES		26,883	16,389
TOTAL EQUITY AND LIABILITIES		220,198	210,652

NOTES

Note 1 General information

Integrum AB (publ) ("Integrum"), corporate ID number 556407-3145 is a parent company registered in Sweden with its registered office in Mölndal, street address Krokslätts Fabriker 50, 431 37 Mölndal, Sweden.

Unless otherwise stated, all amounts are reported in thousands of Swedish kronor (SEK thousand). Information in brackets refers to the comparison period.

Note 2 Summary of key accounting principles

Integrum applies International Financial Reporting Standards (IFRS) as endorsed by the EU. The accounting policies and definitions are consistently applied with those described in the Integrum Annual Report 2021/2022 (available at www.integrum.com). There are no new accounting policies applicable from 2022/2023 that significantly affects Integrum. This interim report has been prepared in accordance with IAS 34 Interim Financial Reporting and the Swedish Annual Accounts Act. The Parent Company applies the Swedish Annual Accounts Act and RFR 2 Reporting for legal entities.

Note 3 Important estimates and assumptions for accounting purposes

The group makes estimates and assumptions regarding the future. The estimates for accounting purposes that result from these will, by definition, rarely correspond to the actual outcome. Estimates and assumptions that entail a significant risk of material adjustment to the recognised amounts for assets and liabilities in the coming financial year are dealt with in general below.

(a) Intangible assets

Development costs that are directly attributable to the development of the group's products are subject to assessments and estimates linked to the possibility of being capitalized as capitalized development assets.

(b) Review of impairment requirements for capitalized expenditure for the development work

Each year the group investigates whether there are any impairment requirements for capitalized expenditure for the development work according to the accounting principle described in note 1. The recoverable amounts for cash-generating units have been established by calculating the value in use.

(c) The term of leases

When the term of the leases is established, management considers all available information that provides a financial incentive to exercise an extension option or not to exercise an option to terminate an agreement. Options to extend an agreement are included in the term of the lease only if it is reasonable to assume that the agreement will be extended (or not terminated). Possible future cash flows of SEK 426 thousand have not been included in leasing liabilities as it is reasonable to assume that the agreements will not be extended.

The assessment will be reassessed if any significant event or change in circumstances occurs that affects this assessment and the change is within the control of the lessee.

(d) Deferred tax assets

The parent company and the group's subsidiaries in the US recognised taxable surpluses in the most recent tax assessment, and the management makes the assessment that continued taxable surpluses will be recognised to such an extent that the taxable deficits in the companies will be used in the foreseeable future. In the financial statements as at 30 April 2023 the company has therefore assessed that reporting a deferred tax asset for the available taxable deficits will be realised. Within the group there are also unrealised internal gains in inventories as a result of sales between the parent company in Sweden and the subsidiary company in the US. The company's assessment is that the goods will be sold externally and that the deferred tax asset linked to these goods will then be realised, which means that this deferred tax asset will also be recognised in the balance sheet

Note 4 Revenue by market

Amounts in SEK thousand	February – April		May – April	
	2022/ 2023	2021/ 2022	2022/ 2023	2021/ 2022
Sweden	1,246	1,225	3,868	4,437
US	14,202	14,430	58,436	43,086
Other countries	2,683	2,668	11,968	8,201
Total	18,131	18,323	74,272	55,724

Note 5 Other operating income

Amounts in SEK thousand	February – April		May – April	
	2022/ 2023	2021/ 2022	2022/ 2023	2021/ 2022
Exchange gains	702	4,970	20,970	15,866
Other income	-	676	-	2,661
Total	702	5,646	20,970	18,527

Note 6 Other operating expenses

Amounts in SEK thousand	February – April		May – April	
	2022/ 2023	2021/ 2022	2022/ 2023	2021/ 2022
Exchange losses	-1,122	-2,450	-15,386	-7,388
Total	-1,122	-2,450	-15,386	-7,388

Note 7 Transactions with related parties

Related party relationships

The parent company has related party relationships with the Integrum Inc. and Integrum Sweden AB subsidiaries. Of the parent company's total income and purchases, SEK 36,912 (43,688) thousand relates to income from the subsidiary and SEK 0 (0) thousand to purchases from the subsidiary.

Amounts in SEK thousand	February – April		May – April	
	2022/2023	2021/2022	2022/2023	2021/2022
Sales to related companies	6,911	16,534	36,912	43,688

Internal prices between group companies are set based on the “arm’s length” principle, i.e. between parties that are independent of each other and well-informed and have an interest in the transactions.

Transactions with key individuals in senior positions

In addition to board fees, the Chair of the Board, Rickard Brånemark, received consultancy fees of SEK 598 (1,741) thousand for clinical expertise work in the quarter. The cost has been recognised in other external expenses. Transactions with related parties take place on market terms.

Amounts in SEK thousand	February – April		May – April	
	2022/2023	2021/2022	2022/2023	2021/2022
Purchases from senior executives	598	1,741	2,306	3,476

Note 8 Earnings per share

	February – April		May – April	
	2022/2023	2021/2022	2022/2023	2021/2022
Consolidated profit/loss for the period, SEK thousand	6,389	3,273	-3,722	21,272
Weighted average number of shares before dilution	18,429,289	17,801,305	18,429,289	17,801,305
Dilution effect of option programs	-	368,350	-	368,350
Weighted average number of shares after dilution	18,429,289	18,169,655	18,429,289	18,169,655
Earnings per share before dilution	0.35	0.18	-0.2	1.19
Earnings per share after dilution	0.35	0.18	-0.2	1.17

Note 10 Financial key ratios

In addition to the financial key ratios that have been prepared in accordance with IFRS, Integrum presents financial key ratios that are not defined according to IFRS, such as the operating margin and equity/assets ratio. These alternative key ratios are considered to be important key results and performance indicators for investors and other users of the interim report. The alternative key ratios must be regarded as a supplement to, and not a replacement for, the financial information that has been prepared in accordance with IFRS. The Integrum group’s definitions of these indicators, which are not defined according to IFRS, are described in this note.

Key ratios	Definition	Reasons for use
Net sales growth	The percentage net sales increase compared with a previous period.	Follow the company’s net sales growth.
Operating profit/loss (EBIT)	Profit/loss before financial items and tax	Follow the company’s profit/loss trend.
Operating margin (EBIT) (%)	EBIT in per cent of the period’s net sales.	Follow the company’s profit/loss trend.
Equity/assets ratio in %	Equity at the end of the period in relation to the balance sheet total at the end of the period	The equity/assets ratio shows the proportion of the balance sheet total that consists of equity and has been included so that investors can get an idea of the company’s capital structure.
Equity per share	Equity divided by the number of shares at the end of the period.	Follow the company’s historical earnings per share.
Employees	The number of employees at the end of the period.	Follow the company’s growth in number of employees

Share warrant program

From October 2020 there was an incentive program, aimed at the board and employees of Integrum AB. The warrants give the holders the right to subscribe to 145,100 series B shares at a subscription price of SEK 37.25 per share between 1 October up to and including 30 November 2023.

From October 2021 there was another incentive program, aimed at the board and employees of Integrum AB. The warrants give the holders the right to subscribe to 142,000 series B shares at a subscription price of SEK 158.16 per share between 1 October up to and including 30 November 2024.

From October 2022 there was yet another incentive program, aimed at the employees of Integrum AB. The warrants give the holders the right to subscribe to 240 000 series B shares at a subscription price of SEK 50.99 per share between 1 October up to and including 30 November 2025.

At the end of the period the company had a total of 3,673 shareholders registered at Euroclear, of which 3,562 (96.98%) are resident in Sweden.

	Number of shareholders	Shareholders (%)	Holding (%)
Sweden	3,562	96.98	83.78
Rest of Nordic region	61	1.66	0.82
Rest of Europe	39	1.06	4.86
US	9	0.25	10.53
Rest of the world	2	0.05	0.00
Total	4,040	100	100

Note 9 Events after the end of the interim period

After the end of the period, the board appointed Scott Flora as an adjunct board member.

There are no other significant events to report after the end of the period.

